Related Experiment Video
Updated: Aug 22, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Antiviral therapy for treatment-naïve hepatitis B virus patients
Daryl T-Y Lau1, Fernando E Membreno
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, The University of Texas Medical Branch, 4.106 McCullough Building, 301 University Boulevard, Galveston, TX 77555-0764, USA. dalau@utmb.edu
Abstract:
Hepatitis B virus infection is a major public health problem worldwide,responsible for considerable morbidity and mortality from chronic liver disease. It is estimated that there are 350 million hepatitis B virus carriers globally. The prevalence of chronic hepatitis B infection varies greatly in different regions of the world. In the United States, approximately 1.5 million people are infected and 50,000 to 100,000 new cases are reported annually despite the availability of effective vaccines. This article reviews various antiviral therapies for treatment naïve hepatitis B virus patients.
Related Concept Videos
Hepatitis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
